BACKGROUND: Connective tissue growth factor (CTGF) has been recently reported as a mediator of myocardial fibrosis; however, the significance of plasma CTGF concentration has not been evaluated in patients with heart failure. The aim of this study was to investigate the clinical utility of plasma CTGF concentration for the diagnosis of heart failure. METHODS AND RESULTS: We evaluated fifty-two patients with chronic heart failure. The plasma concentration of CTGF and other markers of fibrosis were assessed and compared with clinical and echocardiographic data. Plasma CTGF was significantly elevated in symptomatic patients in proportion to their NYHA classes and was significantly correlated with plasma brain natriuretic peptide (BNP) concentration (r=0.395, P<0.01). Plasma CTGF was also correlated with plasma transforming growth factor beta (TGF-beta) (r=0.512, P<0.01), matrix metalloproteinase (MMP)-2 (r=0.391, P<0.05) and tissue inhibitor of MMP (TIMP)-2 (r=0.354, P<0.05) concentrations. Interestingly, plasma CTGF was correlated with E/E' value evaluated by tissue Doppler echocardiography (r=0.593, P=0.012), but not with systolic function and left ventricular mass. CONCLUSION: Our study suggests that plasma CTGF concentration is a novel diagnostic marker for cardiac dysfunction and may provide additional specific information about myocardial fibrosis in chronic heart failure patients.
BACKGROUND:Connective tissue growth factor (CTGF) has been recently reported as a mediator of myocardial fibrosis; however, the significance of plasma CTGF concentration has not been evaluated in patients with heart failure. The aim of this study was to investigate the clinical utility of plasma CTGF concentration for the diagnosis of heart failure. METHODS AND RESULTS: We evaluated fifty-two patients with chronic heart failure. The plasma concentration of CTGF and other markers of fibrosis were assessed and compared with clinical and echocardiographic data. Plasma CTGF was significantly elevated in symptomatic patients in proportion to their NYHA classes and was significantly correlated with plasma brain natriuretic peptide (BNP) concentration (r=0.395, P<0.01). Plasma CTGF was also correlated with plasma transforming growth factor beta (TGF-beta) (r=0.512, P<0.01), matrix metalloproteinase (MMP)-2 (r=0.391, P<0.05) and tissue inhibitor of MMP (TIMP)-2 (r=0.354, P<0.05) concentrations. Interestingly, plasma CTGF was correlated with E/E' value evaluated by tissue Doppler echocardiography (r=0.593, P=0.012), but not with systolic function and left ventricular mass. CONCLUSION: Our study suggests that plasma CTGF concentration is a novel diagnostic marker for cardiac dysfunction and may provide additional specific information about myocardial fibrosis in chronic heart failurepatients.
Authors: Amit Saxena; Peter M Izmirly; Sung Won Han; Paraskevi Briassouli; Tania L Rivera; Hua Zhong; Deborah M Friedman; Robert M Clancy; Jill P Buyon Journal: J Am Coll Cardiol Date: 2015-08-25 Impact factor: 24.094
Authors: Raúl R Rodrigues-Diez; Ana Belen Garcia-Redondo; Macarena Orejudo; Raquel Rodrigues-Diez; Ana Maria Briones; Enrique Bosch-Panadero; Gyorgy Kery; Janos Pato; Alberto Ortiz; Mercedes Salaices; Jesus Egido; Marta Ruiz-Ortega Journal: Antioxid Redox Signal Date: 2015-01-01 Impact factor: 8.401
Authors: Elsa Sánchez-López; Sandra Rayego; Raquel Rodrigues-Díez; Javier Sánchez Rodriguez; Raúl Rodrigues-Díez; Juan Rodríguez-Vita; Gisselle Carvajal; Luiz Stark Aroeira; Rafael Selgas; Sergio A Mezzano; Alberto Ortiz; Jesús Egido; Marta Ruiz-Ortega Journal: J Am Soc Nephrol Date: 2009-05-07 Impact factor: 10.121